Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New gel aims to stop recurring vaginal infections

NCT ID NCT07234786

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a gel device called Multi-Gyn FemiTotal in 80 women with bacterial vaginosis or vaginal yeast infections. Participants use the gel for 7 days, and if symptoms clear, they are followed for 4 months to see if the infection returns. The goal is to see if the gel can both treat and prevent these common infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Age ≥ 18 years old. 2. Women suffering from VVC or BV at the time of inclusion: 3. For VVC: Subject with at least itching score \> 2 and crumbly white discharge. 4. For BV: Subject with at least 3 out of 4 Amsel criteria positive, with at least presence of clue cells (\>20%). Amsel criteria used for the study: * Thin, white, yellow, homogeneous discharge, * Clue cells on wet mount microscopy \>20%, * a vaginal fluid pH ≥4.5 when placing the discharge on litmus paper, * Release fishy odor after adding 10% potassium hydroxide (KOH) solution to wet mount - also known as "whiff test". 5. Subject having given freely and expressly her informed consent. 6. Subject using a contraceptive regimen recognized as effective (pill, implant, Intra Uterine Device (IUD), condoms) since at least 12 weeks before inclusion visit and during the whole study. 7. Subject cooperative and aware of the device's modalities of use and the necessity and duration of the follow-up visits so that perfect adhesion to the protocol can be expected Exclusion Criteria: 1. Pregnant or nursing woman or planning a pregnancy during the study. 2. Subject suspected to be non-compliant according to the investigator's judgment. 3. Subject enrolled in another clinical trial during the study period on the vaginal area. 4. Subject having a known allergy or hypersensitivity to one of the components of the investigational device. 5. Subject suffering from a sexually transmitted gynaecological infection, genital tract infection or aerobic vaginitis (including clinical obvious gonorrhoea, chlamydia trachomatis or mycoplasma genitalium infection with cervicitis, urethritis, salpingitis). 6. Subject with current genital malignancies. 7. Subject who had a chemotherapy treatment in the 6 months before inclusion. 8. Subject who had a radiotherapy treatment in the genito-urinary area in the 12 months before inclusion. 9. Subject using treatment for vaginal conditions, vaginal infections, or other intravaginal treatment at the time of inclusion. 10. Subject using antibiotics for any reason in the 14 days before inclusion. 11. Subject using vaginal douches and who do not wish to refrain using them during the clinical investigation. 12. Subject with a pessary. 13. Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacterial vaginosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dr Farah Bolaky

    RECRUITING

    Quatre Bornes, Mauritius

More trials for these conditions

Other studies related to the condition(s) this trial covers.